BACKGROUND: Survivors of childhood and adolescent cancer are at risk of vaccine preventable diseases and are recommended to receive booster vaccinations post-chemotherapy. The aim of this study was to describe the compliance of post-chemotherapy revaccination of childhood cancer survivors relative to current Australian guidelines. PROCEDURES: A multi-faceted retrospective review of childhood cancer survivors at the Royal Children's Hospital, Melbourne, Australia was undertaken. Immunisation status was reviewed through four sources: (1) hospital records; (2) telephone survey of consenting participants; (3) Australian Childhood Immunization Register (ACIR); and (4) family practitioners immunisation records. Participants were 0-18 years, and at least 6 months post-treatment for their cancer. RESULTS: The study was conducted between March and September 2006. Eighty-nine patients with a median age at diagnosis of 5.3 years were included, 56% of patients had a diagnosis of leukaemia and 44% solid tumours. The median duration since completion of therapy was 3.1 years. Reviewing all sources, 39% (35/89) of participants had no evidence of booster vaccinations post-completion of therapy. Younger age (P = 0.001), and those diagnosed with leukaemia (P = 0.04) were more likely to have received at least one booster vaccine. Forty-seven percent (42/89) had received at least one influenza vaccination. CONCLUSION: This study highlights poor compliance with current guidelines for re-vaccination in survivors of childhood and adolescent cancer. More evidence is required and these re-vaccination guidelines need to take into account treatment intensity. Multi-component strategies are essential to ensure protection from vaccine preventable diseases in this population. Copyright 2009 Wiley-Liss, Inc.
BACKGROUND: Survivors of childhood and adolescent cancer are at risk of vaccine preventable diseases and are recommended to receive booster vaccinations post-chemotherapy. The aim of this study was to describe the compliance of post-chemotherapy revaccination of childhood cancer survivors relative to current Australian guidelines. PROCEDURES: A multi-faceted retrospective review of childhood cancer survivors at the Royal Children's Hospital, Melbourne, Australia was undertaken. Immunisation status was reviewed through four sources: (1) hospital records; (2) telephone survey of consenting participants; (3) Australian Childhood Immunization Register (ACIR); and (4) family practitioners immunisation records. Participants were 0-18 years, and at least 6 months post-treatment for their cancer. RESULTS: The study was conducted between March and September 2006. Eighty-nine patients with a median age at diagnosis of 5.3 years were included, 56% of patients had a diagnosis of leukaemia and 44% solid tumours. The median duration since completion of therapy was 3.1 years. Reviewing all sources, 39% (35/89) of participants had no evidence of booster vaccinations post-completion of therapy. Younger age (P = 0.001), and those diagnosed with leukaemia (P = 0.04) were more likely to have received at least one booster vaccine. Forty-seven percent (42/89) had received at least one influenza vaccination. CONCLUSION: This study highlights poor compliance with current guidelines for re-vaccination in survivors of childhood and adolescent cancer. More evidence is required and these re-vaccination guidelines need to take into account treatment intensity. Multi-component strategies are essential to ensure protection from vaccine preventable diseases in this population. Copyright 2009 Wiley-Liss, Inc.
Authors: James L Klosky; Kathryn M Russell; Jessica L Simmons; Rebecca H Foster; Kelly Peck; Daniel M Green; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2015-04-20 Impact factor: 3.167
Authors: Aleksandra Pettke; Sophie Jocham; Andreas Wiener; Andreas Löcken; Judith Groenefeld; Martina Ahlmann; Andreas H Groll Journal: Support Care Cancer Date: 2017-07-21 Impact factor: 3.603
Authors: Brent R Weil; Arin L Madenci; Qi Liu; Rebecca M Howell; Todd M Gibson; Yutaka Yasui; Joseph P Neglia; Wendy M Leisenring; Susan A Smith; Emily S Tonorezos; Danielle N Friedman; Louis S Constine; Christopher L Tinkle; Lisa R Diller; Gregory T Armstrong; Kevin C Oeffinger; Christopher B Weldon Journal: J Clin Oncol Date: 2018-04-17 Impact factor: 44.544
Authors: In Young Cho; Jung Eun Yoo; Hyeonyoung Ko; Dong Wook Shin; Ji Won Lee; Hee Jo Baek; Nack-Gyun Chung; Ki Woong Sung; Yun-Mi Song Journal: J Cancer Surviv Date: 2019-11-04 Impact factor: 4.442
Authors: Gregory M T Guilcher; Linda Rivard; Jennifer T Huang; Nicola A M Wright; Lynette Anderson; Hesham Eissa; Wendy Pelletier; Shanti Ramachandran; Tal Schechter; Ami J Shah; Ken Wong; Eric J Chow Journal: Lancet Child Adolesc Health Date: 2021-02-16
Authors: Nigel W Crawford; Anthony G Catto-Smith; Mark R Oliver; Donald J S Cameron; Jim P Buttery Journal: BMC Gastroenterol Date: 2011-07-29 Impact factor: 3.067